Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2889)	6/4/2010 3:15:02 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

GNMK was up 5.85% at 2.:25pm but has had some downticks and is now down 1.41% The stock apparently wants to close some of the UG on June 1st, its 2nd day of trading.<g> bigcharts.marketwatch.com GNMK has 4Qs of better revenues and was trimming some it losses, but the loss on the 1stQ (March) was a little higher.<g> It slashed its IPO price and the money it expected to raise by more than 21%.It cut the amount it expected to raise by about $10M to $36.2M. GNMK focuses on molecular tests for a range of conditions, including an FDA approved test for cystic fibrosis. It is developing other tests, including respiratory viruses.Its target markets are hospitals and reference labs. It has said that it plans to spend $15M on test development, $10M for sales & marketing, and the rest for 'general corporate purposes'.<g> The NAZ is now down 74 points getting close to the 2200 level and the DOW down close to 300 points, it seems that it will close below the "Maginot Line". It seems still better to keep the powder dry. <g> Bernard

To: Jibacoa who wrote (2889)	7/14/2010 12:01:46 PM
From: Jibacoa	Respond to of 3722

Re: THR (Euronext) TBGNF (Pink Sheets) On June8 TromboGenics Reported Positive Results from the PIII VMA Trial It presented data from the first successful PIII trial with microplasmin, or TG-MV-006, for the non-surgical treatment of vitreomacular adhesion, or VMA. The trial recruited 326 patients at 42 centers in the US. The second PIII trial in the microplasmin MIVI-Trust program (TG-MV-007) is due to report in the third quarter of 2010. The TG-MV-006 study had met its primary endpoint with 27.7% of the 220 microplasmin treated patients achieving resolution of their VMA at one month, compared to 13.2% of the 106 patients who received a placebo injection, a highly statistically significant result (p=0.003). The data on a per protocol analysis of the microplasmin treated patient population was also presented, all of whom met the study's inclusion criteria, that showed that 30.7% achieved resolution of their VMA (p=0.004). These results had previously been announced in April. The trial evaluated the visual acuity of patients and showed that at the end of the study 25.5% of the microplasmin treated patients had achieved at least a 10 letter improvement in VA without the need for vitrectomy, compared to only 11.3% of the patients who received a placebo injection (p<0.005)> More recently, on July 9, THR together with BioInvent, reported positive results from TB-402 PII of TB-402 at the 21st International Congress on Thrombosis in Milan, Italy. According to the companies, TB-402 (Anti-Factor VIII antibody) is a novel, long acting anticoagulant that is being developed as a single injection for the prevention of venous thromboembolism. The PII results reportedly showed superior antithrombotic activity of TB-402 when compared to enoxaparin with same safety. This PII study was a multicentre, dose-escalating, randomised, open-label trial, evaluating TB-402 against enoxaparin for the prophylaxis of VTE after knee surgery.<g> THR's CEO, Dr. Patrick DeHaes, had an optimistic letter to shareholders on the 2009 annual report. They expect to report the results of the PIIIs on microplasmin later this Summer and are already starting pre-comercialization activities, as they wxpect the results to be favorable.<g> The company is expected to remain focused on Ophthalmic products and probably will license its other also promising products like its TB-402 for anticoagulation and TB-403 for Oncology. The company seems to be making good progress since the IPO in 2006. It was included in the NEXT index and finished the Yr. on a strong financial position after raising 42M euros in November, which they expect will allow them to build their own sales force to market the ophthalmic products they expect to launch after the approval of microplasmin.<g> Of course, there is no ACTAY. The 52 weeks range in the P.S. has been a H of $26.48 & L of $15.44 It presently trading at $20.15 On June 6 Dr. Matthew Benz presented data from the PIII microplasmin trial at World Ophthalmology Congress in Berlin. THR is scheduled to present the results of the 2nd PIII of Microplasmin at the 28th annual meeting of the American Society of Retina Specialists (ASRS) and the 10th EURETINA Congress next month. The schedule of presentations for both upcoming conferences is as follows: ASRS to be held 28 August - 1 September in Vancouver, BC, Canada August 31: Dr. J. Michael Jumper of West Coast Retina and U.C. San Francisco will present results from the TG-MV-007 trial. August 31: Dr. Kirk Packo of Rush University Medical Center, Chicago, will present data from the TG-MV-006 trial. This is the one Yr. chart in euros: bigcharts.marketwatch.com Bernard